Genmab A/S Sponsored ADR $GMAB Shares Purchased by Creative Planning

Creative Planning raised its stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 11.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 65,132 shares of the company’s stock after buying an additional 6,870 shares during the quarter. Creative Planning’s holdings in Genmab A/S were worth $1,346,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of GMAB. Headlands Technologies LLC lifted its position in shares of Genmab A/S by 1,525.0% in the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock valued at $31,000 after acquiring an additional 1,464 shares in the last quarter. CWM LLC lifted its holdings in Genmab A/S by 50.5% in the 2nd quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after purchasing an additional 603 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Genmab A/S by 124.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock worth $38,000 after purchasing an additional 1,070 shares during the last quarter. Parallel Advisors LLC grew its holdings in shares of Genmab A/S by 377.5% during the second quarter. Parallel Advisors LLC now owns 3,720 shares of the company’s stock worth $77,000 after buying an additional 2,941 shares in the last quarter. Finally, Brooklyn Investment Group raised its position in shares of Genmab A/S by 729.3% in the first quarter. Brooklyn Investment Group now owns 4,246 shares of the company’s stock valued at $83,000 after buying an additional 3,734 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Trading Up 1.4%

Shares of Genmab A/S stock opened at $32.37 on Friday. The business’s fifty day moving average price is $30.56 and its 200 day moving average price is $25.49. Genmab A/S Sponsored ADR has a twelve month low of $17.24 and a twelve month high of $33.65. The stock has a market capitalization of $20.78 billion, a P/E ratio of 13.77, a PEG ratio of 1.66 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.17. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $975.40 million. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%. Genmab A/S has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Truist Financial restated a “buy” rating and set a $48.00 target price (down previously from $49.00) on shares of Genmab A/S in a research report on Thursday, November 6th. Zacks Research cut Genmab A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, October 31st. HC Wainwright upped their target price on Genmab A/S from $40.00 to $41.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Johnson Rice restated a “buy” rating on shares of Genmab A/S in a report on Monday, October 27th. Finally, Guggenheim raised shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price objective for the company in a research note on Tuesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $39.75.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.